Despite spending so much medical resources, more than 9,000 people died of lung cancer every year in Taiwan Province Province in the past five years, because although there are more and more treatment methods for lung cancer, and they are gradually becoming individualized, it still shows that lung cancer patients still have insurmountable treatment difficulties. Because targeted therapy in lung cancer treatment can only be used for patients with different types of gene mutations, and some immunotherapy needs to detect the expression of PD-L 1 to screen suitable patients, patients with no gene mutation, inapplicable targeted therapy and high expression of PD-L 1 face treatment bottlenecks.
Gao Shangzhi, chairman of the Taiwan Province Society of Clinical Oncology and director of the Health Management Department of Guangxin Wuhuoshi Memorial Hospital, said: "Recently, a new generation of immunotherapy can be applied to the treatment of stage III and IV lung cancer. For patients who do not apply the target, this immunotherapy does not need to be limited by the detection results of PD-L 1, and all ethnic groups have curative effects, which makes the treatment of lung cancer have a new dawn! A 70-year-old lung cancer patient, Mama Zheng, recalled her despair and helplessness when she first discovered that she was a stage IV lung cancer patient more than a year ago. At that time, she could hardly get up and get out of bed whenever chemotherapy was going on. After experiencing serious side effects of chemotherapy, vomiting and serious hair loss, even my voice became hoarse and uncomfortable, and I was forced to give up my favorite singing and traveling before I got sick. At one time, she almost despaired of life. Later, under the treatment of a new generation of immunotherapy, the treatment process was no longer so unbearable.
Cancer "the worst triple crown"-lung cancer: high mortality rate, high proportion of late detection, the first cause of death for men and women.
Most patients with early lung cancer have no obvious symptoms, so 70% of them have advanced lung cancer when they are diagnosed, and complications may occur during treatment, which makes many patients and their families quite worried. Chen Yumin, chairman of the Taiwan Province Lung Cancer Society and director of the General Chest Department of Taipei Veterans General Hospital, said: "Non-small cell lung cancer accounts for 92% of lung cancer, and 50% of them cannot receive targeted therapy because they have no special genotype. Although the remaining 50% have the opportunity to receive targeted therapy, after a period of treatment, tumor cells will still develop drug resistance, which makes patients encounter great difficulties in treatment. Yu Chen Democratic Ren further pointed out that since the advent of immunotherapy, although the treatment options for lung cancer have been relatively complete and the average survival time has been gradually extended, some lung cancer patients who are suitable for immunotherapy still need to screen suitable patients by detecting the expression of PD-L 1, so that patients without gene mutation and suitable targeted therapy still face the bottleneck of treatment. Recently, the emergence of a new generation of immunotherapy, for patients who have no gene mutation and are not suitable for targeted therapy, can use a new generation of immunotherapy without testing, which will really make the treatment of lung cancer go to a thorough and new generation!
The new dawn of lung cancer treatment! The new generation of immunotherapy has low probability of complications, which helps patients to prolong their life clock.
Director Gao Shangzhi said that the new generation of immunotherapy applied to the treatment of lung cancer in the third and fourth stages directly blocks the combination of PD-L 1 and PD- 1 in the tumor microenvironment, that is, the immune checkpoint inhibitor enhances the anti-tumor immune response by blocking the tumor's inhibitory effect on the immune system. But some immunotherapy still depends on the detection results of PD-L 1. 50%, the new generation immunotherapy is suitable for all kinds of gene detection manifestations, and it is suitable for all patients regardless of the detection results of PD-L 1. In addition, Director Gao Shangzhi added that compared with traditional chemotherapy, immunotherapy can significantly reduce the proportion of serious side effects related to treatment. However, because immunotherapy strengthens the poisoning attack on cancer cells by strengthening the patient's own immune function, it may also lead to the immune system attacking normal tissues and producing side effects. Although the proportion is low, there may still be intractable side effects, such as immune-mediated pneumonia, hepatitis and enteritis. Once the symptoms of pneumonia appear, it is necessary to suspend immunotherapy and treat pneumonia until it improves. If it happens repeatedly, it may make lung cancer unable to get a good treatment. The new generation immunotherapy has a low probability of causing pneumonia, which can significantly prolong the survival time of lung cancer patients. Patients should pay special attention to it during the treatment, and consult with the doctor immediately if there is any discomfort.
Mother Zheng, a 70-year-old patient with advanced lung cancer, is willing to cook for her family every day and live more for her family!
Zheng's 70-year-old mother and her husband retired before she became ill. In the past, she ran her own printing business at home. Because of business needs, she used to go abroad frequently, with an average of 5-6 times a year. Zheng's mother likes singing and traveling at ordinary times, and she began to cough last April. At first, she thought it was a cold and cough. Later, my cough didn't get better and I went to the hospital. Zheng's mother and family were shocked and desperate after being diagnosed with stage IV lung adenocarcinoma. Because of the side effects of chemotherapy, she often feels tired, vomits, coughs and loses hair. Even her throat became hoarse. In severe cases, she can't even get out of bed, which makes her even think. Although there was immunotherapy in the past, there was no way to apply it because of Zheng's low expression of PD-L 1. If chemotherapy produces resistance, there is no medicine available. Fortunately, under the guidance of Chairman Gao Shangzhi looking for suitable treatment methods and suggestions for Zheng's mother, she started a new generation of immunotherapy. Apart from the discomfort caused by chemotherapy, she is in good physical strength now. When she is free, she will walk and exercise in the nearby park for half an hour, and she can also cook for her family herself. Having said that, Zheng's mother said, "It was such an ordinary and ordinary life, but it was the biggest dream I was most looking forward to at that time! I am really grateful to Chairman Gao Shangzhi and his family for encouraging me and not giving up. On the way to treatment, they gave me great confidence. My biggest wish now is to go abroad with my husband and reunite with my long-married daughters! 」
Chairman Gao Shangzhi finally reminded that patients with lung cancer should not only follow the doctor's advice and make regular follow-up visits, but also drink plenty of water, eat healthily and exercise moderately. Moreover, they must give up smoking, and air pollution, soot, second-hand tobacco and asbestos should also be avoided. If you have respiratory discomfort, you must seek medical attention immediately, which must not be ignored.
Topic: PD-L 1, gene mutation, targeted drugs, cancer therapy, lung cancer, lung adenocarcinoma, non-small cell lung cancer.